The launch of new AI-engineered proteins by Bio-Techne is a significant development in the biotech sector, particularly in cell therapy and regenerative medicine. This expansion could lead to increased demand for Bio-Techne's products, potentially driving revenue growth. The use of advanced AI in product development also positions the company as an innovator, which could positively impact its stock price.